Cargando…
P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
Autores principales: | Huhn, S., Poos, A. M., Mai, E. K., Hänel, M., Salwender, H. J., Dürig, J., Blau, I. W., Scheid, C., Weisel, K. C., Munder, M., Berlanga, O., Bertsch, U., Goldschmidt, H., Weinhold, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430058/ http://dx.doi.org/10.1097/01.HS9.0000846392.99356.df |
Ejemplares similares
-
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023) -
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
por: Huhn, S, et al.
Publicado: (2017) -
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016) -
CCM 87.9
Publicado: (1987) -
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)